Brazil Antitrust Regulator Blocks Amil, Health Deals, Folha Says

Brazil’s antitrust regulator will put certain merger and acquisition deals in the health industry on hold because it’s concerned that purchases of hospitals, laboratories and smaller companies by health insurance firms are leading to too much market concentration, Folha de S.Paulo reported, without saying where it got the information.

The regulator, known as Cade, will block the merger of laboratory chain Diagnosticos da America SA (DASA3) and Amil Participacoes SA (AMIL3)’s MD1 Diagnosticos SA until it has completed a final analysis of the transaction, according to the newspaper. Similar steps are being undertaken in relation to Amil’s planned acquisition of Medial Saude SA, Folha said.

Amil didn’t comment when contacted by Folha, according to the newspaper.

To contact the reporter on this story: Karen Eeuwens in London at keeuwens@bloomberg.net

To contact the editor responsible for this story: Telma Marotto at tmarotto1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.